Your support fuels our research to #EndALS! Donate Now


TDI 209

Scientists at the ALS Therapy Development Institute are testing this small molecule in an attempt to address the oxidative stress observed in the cells of PALS.


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

This potential treatment was added in 2015 to our pipeline and is still in the early stages of preclinical research. 

Comment on this Topic

(All comments are moderated before they appear here.)